MCID: PRS069
MIFTS: 12

Prostate Cancer, Progression and Metastasis of malady

Categories: Cancer diseases

Aliases & Classifications for Prostate Cancer, Progression and Metastasis of

Aliases & Descriptions for Prostate Cancer, Progression and Metastasis of:

Name: Prostate Cancer, Progression and Metastasis of 38 13

Classifications:



Summaries for Prostate Cancer, Progression and Metastasis of

MalaCards based summary : Prostate Cancer, Progression and Metastasis of The drugs Bicalutamide and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include prostate.

Related Diseases for Prostate Cancer, Progression and Metastasis of

Symptoms & Phenotypes for Prostate Cancer, Progression and Metastasis of

Drugs & Therapeutics for Prostate Cancer, Progression and Metastasis of

Drugs for Prostate Cancer, Progression and Metastasis of (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 315)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bicalutamide Approved Phase 4,Phase 3,Phase 2,Phase 1 90357-06-5 56069 2375
2
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 53-03-2 5865
3
Dutasteride Approved, Investigational Phase 4,Phase 2 164656-23-9 152945 6918296
4
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
5 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2
6 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
7 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
8 Androgen Antagonists Phase 4,Phase 3,Phase 2,Phase 1
9 Androgens Phase 4,Phase 3,Phase 2,Phase 1
10 Hormones Phase 4,Phase 3,Phase 2,Phase 1
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
13 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
15
Abiraterone acetate Phase 4,Phase 3,Phase 1,Phase 2 154229-18-2 57336518
16 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
17 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
18 5-alpha Reductase Inhibitors Phase 4,Phase 2
19
Nitroglycerin Approved, Investigational Phase 3 55-63-0 4510
20
Prednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 50-24-8 5755
21
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 83-43-2 6741
22
Cyproterone Acetate Approved, Investigational Phase 3 427-51-0
23
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
24
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 50-02-2 5743
25
Testosterone Approved, Investigational Phase 3,Phase 2 58-22-0 6013
26
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
27
Estramustine Approved Phase 3 2998-57-4 18140 259331
28
Mitoxantrone Approved, Investigational Phase 3,Phase 2 65271-80-9 4212
29
Vinblastine Approved Phase 2, Phase 3 865-21-4 13342 241903
30
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
31
Etoposide Approved Phase 3 33419-42-0 36462
32
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
33
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576 3823
34
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
35
Warfarin Approved Phase 3 81-81-2 6691 54678486
36
Succinylcholine Approved Phase 3,Phase 2,Phase 1 306-40-1 5314
37
Diethylstilbestrol Approved Phase 3 56-53-1 3054 448537
38
Nilutamide Approved Phase 3,Phase 2 63612-50-0 4493
39
Flutamide Approved Phase 3,Phase 2 13311-84-7 3397
40
Goserelin Approved Phase 3,Phase 2,Phase 1 65807-02-5 47725 5311128
41
Buserelin Approved Phase 3 57982-77-1
42
Zoledronic acid Approved Phase 3,Phase 2 118072-93-8 68740
43
Leuprolide Approved, Investigational Phase 3,Phase 2 53714-56-0 3911 657181
44
Dalteparin Approved Phase 3 9041-08-1
45
Methyltestosterone Approved Phase 3,Phase 2 58-18-4 6010
46
Radium Ra 223 dichloride Approved, Investigational Phase 3,Phase 2,Phase 1 444811-40-9
47
Salicylic acid Approved, Vet_approved Phase 2, Phase 3 69-72-7 338
48
Lenograstim Approved Phase 3,Phase 1,Phase 2 135968-09-1
49
Vitamin C Approved, Nutraceutical Phase 3,Phase 2 50-81-7 5785 54670067
50
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793

Interventional clinical trials:

(show top 50) (show all 318)
id Name Status NCT ID Phase
1 Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy Completed NCT00470834 Phase 4
2 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years Completed NCT02757963 Phase 4
3 Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent Recruiting NCT02485691 Phase 4
4 A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel Unknown status NCT00764166 Phase 3
5 GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy Unknown status NCT01704274 Phase 3
6 Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer Unknown status NCT00376792 Phase 3
7 Active Surveillance, Radical Prostatectomy, or Radiation Therapy in Treating Patients With Localized Prostate Cancer Unknown status NCT00632983 Phase 3
8 Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Completed NCT00079001 Phase 3
9 S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Completed NCT00134056 Phase 3
10 A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases Completed NCT00554229 Phase 3
11 Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer Completed NCT00003653 Phase 3
12 Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy Completed NCT00283062 Phase 3
13 Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer Completed NCT00519285 Phase 3
14 Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer Completed NCT00004635 Phase 3
15 A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases Completed NCT00699751 Phase 3
16 Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Completed NCT01308580 Phase 3
17 Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone Completed NCT00003884 Phase 3
18 A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer Completed NCT00617669 Phase 3
19 Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate Cancer Completed NCT01819285 Phase 3
20 Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer Completed NCT00769548 Phase 3
21 Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer Completed NCT00316927 Phase 3
22 Prostate Cancer Intervention Versus Observation Trial (PIVOT) Completed NCT00007644 Phase 3
23 Study of Histrelin Subdermal Implant in Patients With Prostate Cancer Completed NCT01394263 Phase 3
24 XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer Completed NCT00417079 Phase 3
25 Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy Completed NCT00065442 Phase 3
26 Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. Completed NCT01310894 Phase 3
27 Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer Completed NCT00423475 Phase 3
28 Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer Completed NCT00004054 Phase 3
29 Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer Completed NCT01057810 Phase 3
30 Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer Completed NCT00003674 Phase 3
31 Study of Immunotherapy to Treat Advanced Prostate Cancer Completed NCT00861614 Phase 3
32 First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy Completed NCT00389155 Phase 2, Phase 3
33 Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14 Recruiting NCT03119857 Phase 3
34 Management of Castration-Resistant Prostate Cancer With Oligometastases Recruiting NCT02685397 Phase 2, Phase 3
35 Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery Recruiting NCT03070886 Phase 2, Phase 3
36 Efficacy Study Evaluating Chemotherapy in Prostate Cancer Recruiting NCT01978873 Phase 3
37 A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse Recruiting NCT01952223 Phase 3
38 Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS) Recruiting NCT02200614 Phase 3
39 Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer Recruiting NCT00667069 Phase 3
40 Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases Recruiting NCT02759783 Phase 2, Phase 3
41 Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Recruiting NCT02003924 Phase 3
42 Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer Recruiting NCT02446444 Phase 3
43 Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel Recruiting NCT02961257 Phase 3
44 Treatment of Prostate Cancer With Docetaxel + Hormonal Treatment Versus Hormonal Treatment in Patients Treated With Radical Radiotherapy Active, not recruiting NCT00653848 Phase 3
45 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Active, not recruiting NCT00869206 Phase 3
46 Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Active, not recruiting NCT00377156 Phase 3
47 Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Active, not recruiting NCT01308567 Phase 3
48 Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis Active, not recruiting NCT01810770 Phase 3
49 A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Active, not recruiting NCT01946204 Phase 3
50 Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer Active, not recruiting NCT00567580 Phase 3

Search NIH Clinical Center for Prostate Cancer, Progression and Metastasis of

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Genetic Tests for Prostate Cancer, Progression and Metastasis of

Anatomical Context for Prostate Cancer, Progression and Metastasis of

MalaCards organs/tissues related to Prostate Cancer, Progression and Metastasis of:

39
Prostate

Publications for Prostate Cancer, Progression and Metastasis of

Variations for Prostate Cancer, Progression and Metastasis of

Expression for Prostate Cancer, Progression and Metastasis of

Search GEO for disease gene expression data for Prostate Cancer, Progression and Metastasis of.

Pathways for Prostate Cancer, Progression and Metastasis of

GO Terms for Prostate Cancer, Progression and Metastasis of

Sources for Prostate Cancer, Progression and Metastasis of

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....